OncoMatch/Clinical Trials/NCT05608200
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Is NCT05608200 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Lenvatinib, sintilimab plus TACE and Lenvatinib plus TACE for hepatocellular carcinoma non-resectable.
Treatment: Lenvatinib, sintilimab plus TACE · Lenvatinib plus TACE — This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced hepatocellular carcinoma (HCC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE C, CNLC IIIA, CNLC IIIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic therapy
Patients who received prior systemic therapy ... for HCC
Cannot have received: immunotherapy
Patients who received prior ... immunotherapy ... for HCC
Cannot have received: TACE
Patients who received prior ... TACE ... for HCC
Cannot have received: transcatheter arterial radioembolization
Patients who received prior ... transcatheter arterial radioembolization (TARE) ... for HCC
Cannot have received: transcatheter arterial embolization
Patients who received prior ... transcatheter arterial embolization (TAE) ... for HCC
Cannot have received: hepatic arterial infusion chemotherapy
Patients who received prior ... hepatic arterial infusion chemotherapy (HAIC) ... for HCC
Cannot have received: radiation therapy
Patients who received prior ... radiation therapy for HCC
Lab requirements
Blood counts
white blood cell count <3.0×10^9/L, platelets <50×10^9/L, prothrombin time prolongation ≥ 4s
Liver function
Child-Pugh class A/B
Child-Pugh class A/B; hematologic examination: white blood cell count <3.0×10^9/L, platelets <50×10^9/L; Prothrombin time prolongation ≥ 4s
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05608200 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage BCLC STAGE C or CNLC IIIA or CNLC IIIB is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages